mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage

By sjmartinez • June 1, 2025

Verdejo HE, Parra V, Del Campo A, Vasquez-Trincado C, Gatica D, Lopez-Crisosto C, Kuzmicic J, Venegas-Zamora L, Zuñiga-Cuevas U, Troncoso MF, Troncoso R, Rothermel BA, Chiong M, Abel ED, Lavandero S. mTOR inhibition triggers mitochondrial fragmentation in cardiomyocytes through proteosome-dependent prohibitin degradation and OPA-1 cleavage. Cell Commun Signal. 2025 May 31;23(1):256. doi: 10.1186/s12964-025-02240-w. PMID: 40450326.

Tags: AMPK, Endocrinology, Mitochondrial fusion, mTOR, Oma1, OPA-1, Prohibitin, Publications, Rapamycin

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in[...]

Care Coordination for High-Need, High-Cost Commercially Insured Patients: A Randomized Clinical Trial

Duru OK, Harwood J, Moin T, Takada S, Tseng CH, Saju R, Lee E, Fatehpuria A, Mangione CM. Care Coordination for High-Need, High-Cost Commercially Insured[...]

Genetic profiling of synchronous pituitary corticotroph adenomas

Zhang D, Tsai K, Santana C, Javaherian K, Lee M, Bergsneider M, Kim W, Wang MB, Vinters HV, Yan W, Heaney AP. Genetic profiling of[...]